Financings Routine −

Light holder MV Capital acquires 5,000 debenture units

Pre-revenue AI diagnostics company closes dilutive financing to fund regulatory milestones amid going concern risks.

By The Northwire Desk — AI Analysis Jun 22, 2026 · 18:41 ALGO · 0.265 Light AI Inc

Executive Summary

Light AI Inc. closed a private placement of secured convertible debenture units with MV Capital LP for gross proceeds of C$5,000,000.
Each unit comprises a $1,000, 12% secured convertible debenture maturing in 24 months and 8,000 common share purchase warrants exercisable at $0.25 per share for 36 months.
Debentures are convertible at $0.125 per share. Interest accrues quarterly and is payable on the earlier of maturity, prepayment, or conversion.
Proceeds are allocated to general working capital, completion of an ISO 13485/QMS audit, and submission for Health Canada registration.
MV Capital LP received an investor rights agreement granting board nomination rights and pro rata participation in future financings.
An ownership cap restricts MV Capital from converting or exercising if it would exceed 19.9% of outstanding shares without shareholder and exchange approvals.
A statutory hold period of four months and one day applies to all securities.

Material Impact

The closing of this financing extends the company's cash runway but introduces significant dilution and expensive debt-like terms.
Potential dilution is substantial: 40 million conversion shares plus 40 million warrant shares could be issued, representing roughly 65% dilution on the current ~122 million share count, though capped at 19.9% without regulatory approval.
The 12% interest rate and low exercise/conversion prices ($0.25 and $0.125 respectively) reflect a high cost of capital, typical for pre-revenue, high-risk companies with limited bargaining power.
The capital is strictly earmarked for near-term regulatory and compliance milestones (ISO audit, Health Canada submission), which are necessary to progress toward the stated mid-2026 commercialization target.
The financing does not materially change the company's pre-revenue status or its reliance on future capital raises to survive.

ALGO · Price

Company Overview

Light AI Inc. is a pre-revenue artificial intelligence diagnostics company developing a smartphone-based Software as a Medical Device (SaMD).
Its flagship product, QuickScan™ Strep A, uses AI algorithms to analyze smartphone images of throats to detect Group A Streptococcus (GAS) infections, eliminating the need for swabs or lab tests.
The platform targets community, school, and urgent-care settings, aiming to reduce unnecessary physician visits and curb antibiotic overuse.
Pre-FDA validation metrics claim 96.57% accuracy and a 100% Negative Predictive Value for distinguishing viral vs. bacterial pharyngitis.
The company is transitioning from product development to commercialization, with a dual-track strategy focusing on US FDA and Health Canada regulatory approvals.

More from Light AI Inc